MicroPort NeuroTech and AOYI Technology Collaborate on Interventional Brain-Computer Interface Rehabilitation System

Source: Xinhua Finance

XINHUA FINANCE, SHANGHAI, May 28 (Reporter Wei Yutian) – On May 28, Hong Kong-listed company MicroPort NeuroTech (02172.HK) and OYMotion reached a strategic partnership in Shanghai. The two parties will focus on brain-computer interfaces, exoskeletonsRobotConduct integrated R&D across two major technological directions to accelerate the practical application of cutting-edge brain science technologies in the medical rehabilitation field.

This collaboration bridges the technological barriers between traditional medical devices and intelligent rehabilitation assistive equipment, with both parties jointly developing an interventional brain-computer interface (BCI) rehabilitation system. In this partnership, Minimally Invasive Brain Science provides proven vascular interventional hardware technology, while OYMotion contributes multi-modal electroencephalogram (EEG) signal decoding technology, achieving a deep integration of these two core competencies. The complete system utilizes intracranial EEG signals as control commands to drive lightweight exoskeleton devices, establishing a comprehensive closed-loop rehabilitation pathway: cortical EEG signal acquisition is performed via the vasculature, followed by real-time signal decoding, exoskeleton actuation, and somatosensory feedback. This process ultimately achieves cerebral cortical functional remodeling, empowering the enterprise to transition into a provider of full-process rehabilitation solutions.

In terms of application scenarios, this system targets the extensive rehabilitation needs for post-stroke hemiplegia in China. Currently, similar overseas technologies primarily focus on the niche demographic of high-level paraplegics, whereas the mind-controlled exoskeleton device being deployed here is mainly designed for patients with stroke-induced hemiplegia. It aims to help patients regain mobility, aligning closely with the rehabilitation healthcare demands of today's aging society.

In addition to prioritizing interventional brain-computer interface (BCI) technology, Minimally Invasive Brain Science is simultaneously pursuing multiple technological pathways and conducting parallel R&D tailored to diverse clinical scenarios. In complex medical fields such as psychiatric disorders, the company employs a disease-specific R&D strategy. Given the significant variations in clinical risks and benefit criteria across different conditions, the industry widely acknowledges that a single technological approach cannot comprehensively address all diagnostic and therapeutic needs. Consequently, a synergistic multi-route strategy encompassing interventional, invasive, and semi-invasive techniques is regarded as a rational choice to effectively balance clinical safety with therapeutic efficacy.

Industry analysts indicate that the core challenges for commercializing brain-computer interfaces (BCIs) in the medical rehabilitation sector consistently center on three key dimensions: clinical safety, signal stability, and implementation costs. By integrating interventional devices with intelligent robotic technology, these two companies have formulated a localized implementation strategy that precisely addresses the critical rehabilitation demand in China. The parallel deployment of multiple technological pathways has also emerged as a mainstream development approach for leading enterprises in China, aimed at mitigating the risks associated with a single technology while expanding application boundaries.

Editor: Tan Rui